文献速递血栓与止血

免疫性血小板减少症患者中针对血小板生成素及其受体的自身抗体

Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia.
PubMed 文献 · Br J Haematol · 2018-03-13

本研究采用液相过量TPO或cMpl抑制步骤提高结合特异性,检测免疫性血小板减少症(ITP)及其他血小板减少症患者中抗TPO、抗cMpl及抗TPO/cMpl复合物自身抗体。活动性ITP中抗TPO抗体阳性9/32(28%),抗cMpl抗体阳性7/32(22%);44%的ITP患者存在抗TPO或抗cMpl自身抗体。这些抗体与ITP疾病严重程度或治疗次数无关,但3例对TPO受体激动剂无应答者中2例有抗TPO抗体。

要点

  • 活动性ITP中抗TPO自身抗体阳性率为9/32(28%),抗cMpl为7/32(22%)。
  • 44%的ITP患者存在抗TPO或抗cMpl自身抗体,其他血小板减少症为40%。
  • 3例TPO受体激动剂无应答者中2例有抗TPO自身抗体。

核心结论

  • 抗TPO和抗cMpl自身抗体与血小板减少症相关,可能在部分ITP患者中具有临床相关性。

研究设计与样本

  • 本研究检测ITP及其他血小板减少症患者中针对TPO、cMpl或TPO/cMpl复合物的自身抗体,采用液相过量TPO或cMpl抑制步骤提高结合特异性。

主要发现

  • 抗TPO自身抗体阳性率:活动性ITP 9/32(28%),缓解期ITP 0/14(0%),非免疫性血小板减少症1/10(10%),健康对照1/11(9%)。
  • 抗cMpl自身抗体阳性率:活动性ITP 7/32(22%),缓解期ITP 1/14(7%),非免疫性血小板减少症3/10(30%),健康对照0/11(0%)。
  • 2例活动性ITP患者有抗TPO/cMpl复合物自身抗体,但无单独抗TPO或抗cMpl抗体。
  • 抗TPO或抗cMpl自身抗体在44%的ITP患者和40%的其他血小板减少症患者中检出。
  • 这些自身抗体与ITP疾病严重程度或接受的ITP治疗次数无关;本队列中3例对TPO受体激动剂无应答,其中2例有抗TPO自身抗体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autoantibodies to thrombopoietin (TPO, also termed THPO) or the TPO receptor (cMpl, also termed MPL) could play a pathological role in immune thrombocytopenia (ITP). In this study, we tested for autoantibodies against TPO, cMpl, or the TPO/cMpl complex in ITP and other thrombocytopenic disorders. Using an inhibition step with excess TPO in fluid-phase to improve binding specificity, the prevalence of anti-TPO autoantibodies was: active ITP: 9/32 (28%); remission ITP: 0/14 (0%); non-immune thrombocytopenias: 1/10 (10%); and healthy controls: 1/11 (9%). Similarly, using an inhibition step with excess cMpl, the prevalence of specific anti-cMpl autoantibodies was: active ITP: 7/32 (22%); remission ITP: 1/14 (7%); non-immune thrombocytopenias: 3/10 (30%); and healthy controls: 0/11 (0%). Two active ITP patients had autoantibodies against the TPO/cMpl complex, but not against TPO or cMpl alone. Anti-TPO or anti-cMpl autoantibodies were found in 44% of ITP patients, and in 40% of patients with other thrombocytopenic disorders. These autoantibodies did not correlate with ITP disease severity or number of ITP treatments received; however, in this cohort, 3 patients failed to respond to TPO receptor agonist medications, and of those, 2 had anti-TPO autoantibodies. This suggests that anti-TPO and anti-cMpl autoantibodies are associated with thrombocytopenia, and may be clinically relevant in a subset of ITP patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Nazy I, Kelton JG, Moore JC, et al. Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia. Br J Haematol. 2018. PMID: 29532903. doi:10.1111/bjh.15165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。